Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway.

Estrogen receptor (ER) is activated either by ligand or by signals from tyrosine kinase-linked cell surface receptors. We investigated whether the nonreceptor Src tyrosine kinase could affect ER activity. Expression of constitutively active Src or stimulation of the endogenous Src/JNK pathway enhances transcriptional activation by the estrogen-ER complex and strongly stimulates the otherwise weak activation by the unliganded ER and the tamoxifen-ER complex. Src affects ER activation function 1 (AF-1), and not ER AF-2, and does so through its tyrosine kinase activity. This effect of Src is mediated partly through a Raf/mitogen-activated ERK kinase/extracellular signal-regulated kinase (Raf/MEK/ERK) signaling cascade and partly through a MEKK/JNKK/JNK cascade. Although, as previously shown, Src action through activated ERK stimulates AF-1 by phosphorylation at S118, Src action through activated JNK neither leads to phosphorylation of S118 nor requires S118 for its action. We therefore suggest that the Src/JNK pathway enhances AF-1 activity by modification of ER AF-1-associated proteins. Src potentiates activation functions in CREB-binding protein (CBP) and glucocorticoid receptor interacting protein 1 (GRIP1), and we discuss the possibility that the Src/JNK pathway enhances the activity of these coactivators, which are known to mediate AF-1 action.

[1]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.

[2]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[3]  D. Slamon,et al.  HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer , 1997, Stem cells.

[4]  O. Linderkamp,et al.  L‐selectin activates JNK via src‐like tyrosine kinases and the small G‐protein Rac , 1997, Immunology.

[5]  M. Parker.  Antiestrogen-estrogen receptor interactions. , 1996, Cancer treatment and research.

[6]  E. Zandi,et al.  Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity , 1997, Molecular and cellular biology.

[7]  D. Vorojeikina,et al.  Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation. , 1999, Biochemistry.

[8]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[9]  D. Metzger,et al.  Purification and Identification of p68 RNA Helicase Acting as a Transcriptional Coactivator Specific for the Activation Function 1 of Human Estrogen Receptor α , 1999, Molecular and Cellular Biology.

[10]  H. Herschman,et al.  v-src Induces Prostaglandin Synthase 2 Gene Expression by Activation of the c-Jun N-terminal Kinase and the c-Jun Transcription Factor (*) , 1995, The Journal of Biological Chemistry.

[11]  W. Muller,et al.  Activation of the Src family of tyrosine kinases in mammary tumorigenesis. , 1994, Advances in cancer research.

[12]  M. Karin,et al.  Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 , 1991, Nature.

[13]  G. Greene,et al.  Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. , 1999, Molecular endocrinology.

[14]  P. Chambon,et al.  Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. , 1995, Molecular endocrinology.

[15]  C. Glass,et al.  Nuclear receptor coactivators. , 1997, Current opinion in cell biology.

[16]  P. Chambon,et al.  The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. , 1989, The EMBO journal.

[17]  F. Jeanmougin,et al.  A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. , 1996, The EMBO journal.

[18]  C. Glass,et al.  Transcription factor-specific requirements for coactivators and their acetyltransferase functions. , 1998, Science.

[19]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[20]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[21]  S. Berger,et al.  CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. , 1997, Cancer research.

[22]  P. Webb,et al.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.

[23]  J. Baxter,et al.  The limits of the cellular capacity to mediate an estrogen response. , 1992, Molecular endocrinology.

[24]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[25]  Y. Sadovsky,et al.  Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein , 1995, Molecular and cellular biology.

[26]  Carolyn L. Smith,et al.  Cross-talk between peptide growth factor and estrogen receptor signaling pathways. , 1998, Biology of reproduction.

[27]  M. Karin,et al.  Selective activation of the JNK signaling cascadeand c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs , 1995, Cell.

[28]  B. Howard,et al.  A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A , 1996, Nature.

[29]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[30]  G. Staal,et al.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.

[31]  B. Katzenellenbogen,et al.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. , 1996, Molecular endocrinology.

[32]  J. Parsons,et al.  Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. , 1997, Current opinion in cell biology.

[33]  Y. Berthois,et al.  Estradiol membrane binding sites on human breast cancer cell lines. Use of a fluorescent estradiol conjugate to demonstrate plasma membrane binding systems. , 1986, Journal of steroid biochemistry.

[34]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Karin,et al.  JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.

[36]  E. Kalkhoven,et al.  Isoforms of steroid receptor co‐activator 1 differ in their ability to potentiate transcription by the oestrogen receptor , 1998, The EMBO journal.

[37]  M. Imhof,et al.  Cellular Mechanisms Which Distinguish between Hormone‐ and Antihormone‐Activated Estrogen Receptor , 1995, Annals of the New York Academy of Sciences.

[38]  D. Vorojeikina,et al.  Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. , 1997, Molecular endocrinology.

[39]  E. Kalkhoven,et al.  Ligand‐independent activation of the oestrogen receptor by mutation of a conserved tyrosine , 1997, The EMBO journal.

[40]  M. Karin,et al.  Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. , 1995, Science.

[41]  B. Katzenellenbogen,et al.  Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.

[42]  P. Chambon,et al.  Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region. , 1993, The EMBO journal.

[43]  A. Bilancio,et al.  The role of estradiol receptor in the proliferative activity of vanadate on MCF-7 cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[44]  H. Gronemeyer,et al.  The coactivator TIF2 contains three nuclear receptor‐binding motifs and mediates transactivation through CBP binding‐dependent and ‐independent pathways , 1998, The EMBO journal.

[45]  Parker Mg.  Transcriptional activation by oestrogen receptors. , 1998 .

[46]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular Endocrinology.

[47]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.

[48]  P. Cohen,et al.  Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. , 1986, The Journal of biological chemistry.

[49]  Masahiko Hibi,et al.  c-Jun Can Recruit JNK to Phosphorylate Dimerization Partners via Specific Docking Interactions , 1996, Cell.

[50]  B. Katzenellenbogen,et al.  Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation* , 1996, The Journal of Biological Chemistry.

[51]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[52]  M. Stallcup,et al.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[53]  M. Karin,et al.  Control of AP-1 activity by signal transduction cascades. , 1993, Advances in second messenger and phosphoprotein research.

[54]  M. Karin,et al.  Induction of c‐fos expression through JNK‐mediated TCF/Elk‐1 phosphorylation. , 1995, The EMBO journal.

[55]  C. Green,et al.  Two separate mechanisms for ligand-independent activation of the estrogen receptor. , 1997, Molecular endocrinology.

[56]  B. Katzenellenbogen,et al.  Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. , 1994, The Journal of biological chemistry.

[57]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[58]  C. Allis,et al.  Steroid receptor coactivator-1 is a histone acetyltransferase , 1997, Nature.

[59]  G. Rijksen,et al.  c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS , 1996, The Journal of pathology.

[60]  D. Lannigan,et al.  Estradiol-induced Phosphorylation of Serine 118 in the Estrogen Receptor Is Independent of p42/p44 Mitogen-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.

[61]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[62]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[63]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[64]  M. T. Brown,et al.  Regulation, substrates and functions of src. , 1996, Biochimica et biophysica acta.

[65]  H. Rübsamen,et al.  Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. , 1983, Cancer research.

[66]  M. Karin,et al.  Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. , 1993, Genes & development.

[67]  B. Katzenellenbogen,et al.  The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. , 1999, Molecular endocrinology.

[68]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[69]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[70]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[71]  K. Korach,et al.  Cross talk between peptide growth factor and estrogen receptor signaling systems. , 1995, Environmental health perspectives.

[72]  G. Coetzee,et al.  Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins , 1999, Molecular and Cellular Biology.

[73]  K. Korach,et al.  Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. , 1996, Endocrinology.

[74]  M. Montminy,et al.  Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.

[75]  Hui Li,et al.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  N. Koibuchi,et al.  TRAM-1, A Novel 160-kDa Thyroid Hormone Receptor Activator Molecule, Exhibits Distinct Properties from Steroid Receptor Coactivator-1* , 1997, The Journal of Biological Chemistry.

[77]  L. E. Stevenson,et al.  Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the RAS signaling pathway , 1996, International journal of cancer.

[78]  D. Livingston,et al.  The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[79]  D. Vorojeikina,et al.  Phosphorylation of Tyrosine 537 on the Human Estrogen Receptor Is Required for Binding to an Estrogen Response Element (*) , 1995, The Journal of Biological Chemistry.

[80]  P. Chambon,et al.  Characterization of the Amino-terminal Transcriptional Activation Function of the Human Estrogen Receptor in Animal and Yeast Cells (*) , 1995, The Journal of Biological Chemistry.

[81]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[82]  S. Barnes,et al.  Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[83]  G. Jenster,et al.  Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. , 1997, Recent progress in hormone research.

[84]  R. Hoffman.  Potent inhibition of breast cancer cell lines by the isoflavonoid kievitone: comparison with genistein. , 1995, Biochemical and biophysical research communications.